Compared with XRCC4 Y66F mutant, XRCC4 WT tumor showed resistance to chemotherapy treatment; in contrast, LDHi treatment significantly diminished the differential response to chemotherapy (Figure 6D–F). This evidence concerns the gene XRCC4 and neoplasm.